Foghorn Therapeutics Inc. reports results for the quarter ended in September 30 - Earnings Summary
05/11/2024 07:53
* Foghorn Therapeutics Inc. FHTX.OQ reported a quarterly
adjusted loss of 31 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -34 cents. The mean expectation of
five analysts for the quarter was for a loss of 44 cents per
share. Wall Street expected results to range from -56 cents
to -35 cents per share.
* Revenue fell 55.3% to $7.81 million from a year ago;
analysts
expected $6.34 million.
* Foghorn Therapeutics Inc.'s reported EPS for the quarter
was a
loss of 31 cents.
* The company reported a quarterly loss of $19.12 million.
* Foghorn Therapeutics Inc. shares had fallen by 11.5% this
quarter and gained 27.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 11.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Foghorn
Therapeutics Inc. is $17.00
This summary was machine generated from LSEG data November 5 at
07:53 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.44 -0.31 Beat
Jun. 30 2024 -0.65 -0.45 Beat
Mar. 31 2024 -0.63 -0.59 Beat
Dec. 31 2023 -0.76 -0.57 Beat